{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"15"}]}],"title":"by Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"22"}]}],"title":"by Week 48"},{"categories":[{"measurements":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"22"}]}],"title":"by Week 72"},{"categories":[{"measurements":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"22"}]}],"title":"by Week 96"},{"categories":[{"measurements":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"22"}]}],"title":"by Week 120"},{"categories":[{"measurements":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"22"}]}],"title":"by Week 144"}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"description":"Cytogenic response included Complete, Partial, Major, Minor, Minimal and no response. Cytogenetic response was assessed as the percentage of Ph+ metaphases in the bone marrow and is defined as the following: Complete (CCyR) - 0% Ph+ metaphases; Partial (PCyR) - \\>0 to 35% Ph+ metaphases; Major (MCyR) - 0 to 35% Ph+ metaphases; Minor (mCyR) - \\>35 to 65% Ph+ metaphases; Minimal - \\>65 to 95% Ph+ metaphases; None - \\>95 to 100% Ph+ metaphases.","groups":[{"description":"Participants randomized to asciminib 40mg BID","id":"OG000","title":"Asciminib"},{"description":"Participants randomized to bosutinib 500mg QD","id":"OG001","title":"Bosutinib"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"CCyR analysis set is a subset of FAS and included participants who were not in CCyR at baseline. FAS comprised of all randomized participants.","reportingStatus":"POSTED","timeFrame":"by 24, 48, 72, 96, 120 and 144 weeks","title":"Complete Cytogenetic Response Rate by Scheduled Time Points","type":"SECONDARY","unitOfMeasure":"Participants"}